Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia

Annals of Hematology

Volumn 89, Issue 3, 2010, Pages 299-303

  Gómez Almaguer, David ^a   Jaime Párez, Josá Carlos ^a   Garza Rodríguez, Verónica ^a   Chapa Rodríguez, Adrián ^a   Tarín Arzaga, Luz ^a   Herrera Garza, Josá Luís ^a   Ruiz Argüelles, Guillermo J ^b,c   López Otero, Avril ^b   González Llano, Oscar ^a   Rodríguez Romo, Laura ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^c Laboratorios Clinicos de Puebla   (Mexico)

Author keywords

Alemtuzumab; Aplastic anemia; Immunosuppressive therapy; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; HEMOGLOBIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; VIRUS REACTIVATION; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949321839     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0816-5     Document Type: Article

References (26)

1. Marsh J (2006) Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program 2006:78-85
2. Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:2509-2519
3. Marsh JC, Ball SE, Darbyshire P et al (2003) Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 123:782-801
4. Jaime-Perez JC, Ruiz-Arguelles GJ, Gomez-Almaguer D (2005) Haematopoietic stem cell transplantation to treat aplastic anaemia. Expert Opin Biol Ther 5:617-626 (Pubitemid 40780546)
5. Brodsky RA, Jones RJ (2005) Aplastic anaemia. Lancet 365:1647-1656
6. Johnston B, Conly J (2006) Alemtuzumab and natalizumab: the monoclonal antibody story continues. Can J Infect Dis Med Microbiol 17:327-329
7. Villamor N, Montserrat E, Colomer D (2003) Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 30:424-433
8. Willis F, Marsh JC, Bevan DH et al (2001) The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 114:891-898
9. Marsh JC (2007) Treatment of acquired aplastic anemia. Haematologica 92:2-5
10. Issaragrisil S, Kaufman DW, Anderson T et al (2006) The epidemiology of aplastic anemia in Thailand. Blood 107:1299-1307
11. Kaufman DW, Kelly JP, Jurgelon JM et al (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 60:23-30
12. Montane E, Ibanez L, Vidal X et al (2008) Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 93:518-523
13. Ruiz-Arguelles GJ, Gomez-Rangel JD (2003) Long-term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: a single institution study. Acta Haematol 110:184-187
14. Benitez-Aranda H, Velez-Ruelas MA, Diaz-Cardenas S et al (2002) Incidence of aplastic anemia in a defined subpopulation from Mexico City. Hematology 7:229-232
15. Storb R, Leisenring W, Anasetti C et al (1997) Long-term followup of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 89:3890-3891
16. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H (2003) Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101:1236-1242
17. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D (2001) High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 66:71
18. Brodsky RA, Sensenbrenner LL, Smith BD et al (2001) Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 135:477-483
19. Chao MM, Levine JE, Ferrara JL et al (2008) Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H. Pediatr Blood Cancer 50:917-919
20. Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR (2007) Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 65:333-338
21. Hale G, Rebello P, Brettman LR et al (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948-955
22. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL (2005) Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 29:1213-1215
23. Rzepecki P, Sarosiek T, Szczylik C (2006) Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome- single center experience. Jpn J Clin Oncol 36:46-49
24. Gómez-Almaguer D, Ruiz-Argüelles GJ, del Carmen Tarín- Arzaga L et al (2008) Alemtuzumab for the treatment of steroidrefractory acute graft-versus-host disease. Biol Blood Marrow Transplant 14:10-15
25. Ruiz-Argüelles GJ, Gil-Beristain J, Magaña M, Ruiz-Delgado GJ (2008) Alemtuzumab-induced resolution of refractory cutaneous chronic graft versus host disease. Biol Bone Marrow Transplant 14:7-9
26. Kim H, Min YJ, Baek JH, Shin SJ, Lee EH, Noh EK, Kim MY, Park JH et al (2009) A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 33:222-231